A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Tycel J Phillips,Abraham Avigdor,Ronit Gurion,Caterina Patti,Paolo Corradini,Monica Tani,Amitkumar Mehta,Izidore S Lossos,Pier Luigi Zinzani,Catherine Thieblemont,Wojciech Jurczak,Fred Zheng,Erica Rappold,Wanying Zhao, Ping Jiang,Peter Johnson

Blood advances（2023）

引用 0|浏览0

暂无评分

摘要

•Parsaclisib, a highly selective, potent PI3Kδ inhibitor, demonstrated durable responses and an overall manageable safety in R/R MZL•Investigation is needed to determine patients who may benefit from PI3K pathway inhibition as an alternative to ≥2L standard-care agents

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要